Latest Content

The FDA has approved Hyrnuo for some with locally advanced or metastatic non-squamous non–small cell lung cancer with activating mutations.

The FDA approved Imdelltra after a study showed longer survival compared with chemotherapy in advanced small cell lung cancer.

I never dreamed a stranger could teach me so much about cancer, life and living with gratitude but I'm so glad she did!

Dr. Jorge E. Cortes discussed the evolution of chronic myeloid leukemia treatment and emerging strategies aimed at improving outcomes and quality of life.

The oral therapy DPTX3186 received fast track status to help speed development of a potential new option for patients with gastric cancer.

Dr. Pamela L. Kunz sat down with CURE to discuss Neuroendocrine Tumors, or NETs, Awareness Month.

Dr. Benjamin Herzberg spotlighted some of the “weird and wacky” new ideas in the field of targeted therapies for the treatment of lung cancer.

Dr. Adam J. Schoenfeld delivered an extensive overview of how cellular therapies are shaping the future of lung cancer care.

Dr. Catherine A. Shu highlights targeted therapies for patients with lung cancer, emphasizing advances, challenges and the importance of clinical trials.

The FDA has granted fast track designation to ITM-94 as a diagnostic agent for the detection of the most common type of kidney cancer.

The FDA has approved Epkinly plus Revlimid and Rituxan for the treatment of patients with relapsed or refractory follicular lymphoma.

Steve Brown and Lisa Booth explain how AI platforms like CureWise offer clarity, reduce anxiety, and support informed decisions during the cancer journey.

I am thankful that a nurse navigator gave me continuity of compassionate care that helped me to heal from the inside out.